Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04183218 | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes | completed | — | 24 | Mayo ClinicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification(SACHI) | completed | Phase 3 | 216 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT04768075 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | completed | Phase 3 | 60 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05928299 | Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer(IMOTION) | completed | — | 150 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC(DUBLIN-3) | completed | Phase 3 | 559 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT06713564 | A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer | completed | Phase 1 | 24 | Integro TheranosticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 174 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05599321 | Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling | completed | — | 110 | Penn State UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06255041 | Detection of Cancer in Breath Samples by Trained Detection Dogs | completed | — | 1,386 | SpotitEarlyINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07591376 | A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers(APART-LUNG) | completed | N/A | 30 | University Hospital Schleswig-HolsteinOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04087473 | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC | completed | — | 50 | National Cancer Centre, SingaporeOTHER | 4 | May 13, 2026 | clinicaltrials |
| NCT05617742 | Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer | completed | N/A | 58 | Chang Gung Memorial HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06145048 | Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.(VISUALIZE) | completed | Phase 2 | 89 | Vergent Bioscience, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT06939049 | Development of New Methodologies and Innovative Tools for the diagnoSi and Therapeutic Treatment of uMAni Epithelial Tumors(SISTEMA) | completed | — | 250 | ASL LecceOTHER_GOV | 1 | May 13, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04010357 | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04042558 | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies(GFPC 06-2018) | completed | Phase 2 | 150 | Centre Francois BaclesseOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT05453721 | Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）(IMPLANE-0529) | completed | N/A | 272 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02314481 | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity(DARWINII) | completed | Phase 2 | 50 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02496624 | Cone-beam CT Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS) | completed | N/A | 40 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT06236516 | One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors(ONE STOP) | completed | N/A | 10 | Washington University School of MedicineOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559526 | Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib(NUTRI-CPNM) | completed | — | 25 | Fundacin Biomedica Galicia SurOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06613633 | Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC | completed | — | 4,000 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT00883480 | Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma(SLAT) | completed | N/A | 153 | Spanish Lung Cancer GroupOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | completed | Phase 2 | 423 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer(FLT3) | completed | Phase 2 | 33 | Montefiore Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05224180 | OSA in Never Smokers With Lung Cancer | completed | — | 77 | Seoul National University HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00945451 | Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer | completed | N/A | 35 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01207986 | Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study(EP48 HIV CHEST) | completed | N/A | 450 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03481114 | Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer(REPAINT) | completed | Phase 2 | 55 | Albert Einstein College of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06380361 | InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology(INSPECT) | completed | N/A | 30 | SensomeINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
| NCT05519865 | A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | completed | Phase 2 | 118 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07532447 | Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate | completed | — | 74 | People's Hospital of Xinjiang Uygur Autonomous RegionOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06286592 | LUNGevity: Lung Cancer Stigma Community Based Participatory Research | completed | N/A | 108 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02816697 | Implementation of a System-level Tobacco Treatment Intervention | completed | N/A | 263 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03634241 | Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04479306 | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07532057 | The Effect of Pulmonary Rehabilitation on Pulmonary Function Tests, Exercise Capacity, and Quality of Life in Patients With Advanced-Stage Lung Cancer Receiving Chemotherapy(PR-LUNGCA-2019) | completed | N/A | 30 | Istanbul Medipol University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials